Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.24.0.1
Consolidated Balance Sheets - USD ($)
Nov. 30, 2023
Nov. 30, 2022
Current Assets    
Cash and cash equivalents $ 406,067 $ 1,703,958
Marketable securities 574,183 17,620
Accounts receivable (net of allowance for doubtful accounts of $3,822,300 and $3,528,119, respectively) 6,576,240 6,043,941
Prepaid expenses 615,407 566,557
Inventory, current portion 768,877 851,230
Swap contract 122,113 0
Other current assets 389,950 426,879
Total current assets 9,452,837 9,610,185
Property and Equipment-net 20,996,883 13,603,115
Other Assets    
Duke license agreement, net 0 13,691,028
Intangible assets, net 989,121 1,463,312
Inventory, net of current portion 5,260,119 9,275,344
Goodwill 1,941,411 1,941,411
Deferred tax assets 20,492,749 13,742,399
Operating lease right-of-use asset 1,033,157 606,034
Deposits and other assets, net 746,493 647,226
Total noncurrent assets 30,771,050 41,674,754
Total assets 61,220,770 64,888,054
Current Liabilities    
Accounts payable 3,174,584 1,605,301
Accrued expenses 5,170,809 3,585,810
Note payable 165,641 150,527
Line Of credit 1,222,728 2,272,728
Current portion of operating lease liability 225,686 297,691
Duke license agreement liability 1,200,000 1,983,036
Deferred revenue 9,704,553 9,586,327
Total current liabilities 20,864,001 19,481,420
Other Liabilities    
Deferred revenue, net of current portion 41,186,800 36,000,059
Contingent consideration 44,226 1,162,704
Note payable, net of current portion and debt issuance costs 8,430,037 8,579,875
Operating lease long-term liability 851,938 313,298
Long-term liability - revenue sharing agreements 875,000 875,000
Total other liabilities 51,388,001 46,930,936
Total liabilities 72,252,002 66,412,356
Commitments and contingencies (Note 12) 0 0
Stockholders' Deficit    
Preferred stock 0 0
Common stock ($.01 par value, 20,000,000 authorized; 14,849,246 issued and 8,286,785 outstanding as of November 30, 2023 and 14,848,001 issued and 8,500,511 outstanding as of November 30, 2022) 148,492 148,480
Additional paid-in capital 43,411,143 42,597,380
Treasury stock, at cost (23,431,685) (22,632,649)
Accumulated deficit (31,159,182) (21,637,513)
Total stockholders' deficit (11,031,232) (1,524,302)
Total liabilities and stockholders' deficit 61,220,770 64,888,054
Series A Junior Participating Preferred Stock [Member]    
Stockholders' Deficit    
Preferred stock 0 0
Tianhe Stem Cell Biotechnologies Inc [Member]    
Other Assets    
Investment $ 308,000 $ 308,000